Abstract
Background
X-linked agammagobulinemia (XLA) is a primary immunodeficiency caused by Bruton’s tyrosine kinase (BTK) gene mutation. XLA patients have an extremely small amount of peripheral B cells and profound deficiency in all immunoglobulin isotypes. We analyzed the clinical, immunologic, and molecular characteristics of children with XLA in an attempt to improve the diagnosis and treatment of XLA in China.
Methods
Twenty children with XLA-compatible phenotypes from 18 unrelated families were enrolled in this study. The BTK gene was amplified and sequenced, followed by mutation analysis in these children and their female relatives.
Results
Eighteen different mutations of the BTK gene were identified in the 20 patients. Eleven mutations had been reported previously including eight missense mutations (c.994C>T, c.1987C>A, c.1885G>T, c.502T>C, c.1085C>T, c.1816C>T, c.214C>T, c.1912G>A) and three nonsense mutations (c.1267T>A, c.1793C>G, c.1618C>T). Seven novel mutations of the BTK gene were also presented and included five missense mutations (c.134T>A, c.1646T>A, c.1829C>G, c.711G>T, c.1235G>A), one splice-site mutation (c.523+1G>A) and one insertion mutation (c.1024-1025in sTTGCTAAAGCAACTGCTAAAGCAAG). Eight out of 18 mutations of the BTK gene were located in the TK domain, 4 in the PH domain, 4 in the SH2 domain and 2 in the TH domain. Genetic study for carrier status was carried out in 18 families with definite BTK gene mutations. Nine carriers with BTK gene mutations were identified. Six families without carriers were detected, and 3 patients were not tested in this study.
Conclusion
Our results support that molecular genetic testing represents an important tool for early confirmed diagnosis of congenital agammaglobulinemia and may allow accurate carrier detection and prenatal diagnosis.
This is a preview of subscription content, log in via an institution to check access.
References
Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722–728.
Nomura K, Kanegane H, Karasuyama H, Tsukada S, Agematsu K, Murakami G, et al. Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway. Blood 2000;96:610–617.
Vetrie D, Vorechovský I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226–233.
Wang XC, Wang Y, Kanegane H, Toshio M, Yu YH. Gene diagnosis of X-linked agammaglobulinemia. Zhonghua Er Ke Za Zhi 2005;43:449–452.
Lee PP, Chen TX, Jiang LP, Chan KW, Yang W, Lee BW, et al. Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia. J Clin Immunol 2010;30:121–131.
Wang Y, Kanegane H, Wang X, Han X, Zhang Q, Zhao S, et al. Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China. J Clin Immunol 2009;29:352–356.
Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999;93:190–197.
Brooimans RA, van den Berg AJ, Rijkers GT, Sanders LA, van Amstel JK, Tilanus MG, et al. Identification of novel Bruton’s tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia. J Med Genet 1997;34:484–848.
Vorechovský I, Vihinen M, de Saint Basile G, Honsová S, Hammarström L, Müller S, et al. DNA-based mutation analysis of Bruton’s tyrosine kinase gene in patients with X-linked agammaglobulinaemia. Hum Mol Genet 1995;4:51–58.
Ochs HD, Notarangelo LD. X-linked immunodeficiencies. Curr Allergy Asthma Rep 2004;4:339–348.
Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002;141:566–571.
Stewart DM, Lian L, Nelson DL. The clinical spectrum of Bruton’s agammaglobulinemia. Curr Allergy Asthma Rep 2001;1:558–565.
Zhang ZY, Zhao XD, Jiang LP, Liu EM, Wang M, Yu J, et al. Clinical characteristics and molecular analysis of 21 Chinese children with congenital agammaglobulinemia. Scand J Immunol 2010;72:454–459.
Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet 1998;62:1034–1043.
Wicker LS, Scher I. X-linked immune deficiency (xid) of CBA/N mice. Curr Top Microbiol Immunol 1986;124:87–101.
Rawlings DJ, Witte ON. Bruton’s tyrosine kinase is a key regulator in B-cell development. Immunol Rev 1994;138:105–119.
Smith CI, Islam KB, Vorechovský I, Olerup O, Wallin E, Rabbani H, et al. X-linked agammaglobulinemia and other immunoglobulin deficiencies. Immunol Rev 1994;138:159–183.
Kanegane H, Futatani T, Wang Y, Nomura K, Shinozaki K, Matsukura H, et al. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J Allergy Clin Immunol 2001;108:1012–1020.
Holinski-Feder E, Weiss M, Brandau O, Jedele KB, Nore B, Bäckesjö CM, et al. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 uniquemutations without correlation to clinical course. Pediatrics 1998;101:276–284.
Lindvall JM, Blomberg KE, Väliaho J, Vargas L, Heinonen JE, Berglöf A, et al. Bruton’s tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005;203:200–215.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Qin, X., Jiang, LP., Tang, XM. et al. Clinical features and mutation analysis of X-linked agammaglobulinemia in 20 Chinese patients. World J Pediatr 9, 273–277 (2013). https://doi.org/10.1007/s12519-013-0400-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-013-0400-x